Medicine and Dentistry
Abdominal Fat
7%
Adult
35%
Age
9%
Amaurosis
18%
Antiretroviral Therapy
100%
Arm
15%
Assessment
7%
Biological Marker
7%
Bone Density
27%
Cardiovascular Disease
18%
Cell Count
41%
Cells
29%
Chemotherapeutic Agent
18%
Combination Therapy
43%
Computer Assisted Tomography
7%
COVID-19
23%
D-Dimer
7%
Death
25%
Disease
18%
Drug
18%
Ebolavirus
9%
Follow up
20%
Group Therapy
8%
Hazard Ratio
12%
Health
13%
Hip
7%
Hospital
6%
Human Immunodeficiency Virus
63%
Human Immunodeficiency Virus Infection
25%
Inpatient
18%
Intention-to-Treat Analysis
6%
Measurement
7%
Monitoring
13%
Monoclonal Antibody
7%
Motivation
6%
Osteolysis
12%
Patient
45%
Person
19%
Placebo
29%
Proportional Hazards Model
8%
Randomized Controlled Trial
6%
RNA
6%
Spine
9%
T-Helper Cell
13%
Task Performance
8%
Therapeutic Procedure
60%
Treatment Interruption
7%
Vaccine
11%
Virus Infection
7%
Virus RNA
8%
Nursing and Health Professions
Adult
5%
Analysis
6%
Antiretroviral Therapy
62%
Biological Marker
5%
Blindness
12%
Body Composition
6%
Bone Density
17%
CD4 Lymphocyte Count
19%
Combination Therapy
27%
Confidence Interval
9%
Cost Effectiveness Analysis
5%
Death
8%
Diseases
6%
Drug
8%
Efavirenz
6%
Fat
5%
Follow up
12%
Group Therapy
5%
Heart Muscle Ischemia
5%
Human Immunodeficiency Virus Infection
12%
Hyperimmune Globulin
5%
Immunoglobulin
5%
Intention to Treat Analysis
7%
Ischemic Heart Disease
5%
Metabolic Parameters
5%
Monoclonal Antibody
6%
Odds Ratio
9%
Patient
7%
Placebo
17%
Prevention
5%
Quality of Life
12%
Receiver Operating Characteristic
5%
Time
8%
Treatment Interruption
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acquired Immune Deficiency Syndrome
11%
Adverse Event
6%
All Cause Mortality
6%
Antibody
7%
Antivirus Agent
6%
Biological Marker
11%
Blindness
18%
Cardiovascular Disease
8%
Case-Control Study
5%
Circulating microRNA
5%
Clinical Trial
5%
Coronavirinae
8%
Death
16%
Dioxygenase
5%
Diseases
21%
Drug
10%
Ebola Hemorrhagic Fever
5%
Ebola Virus Disease
7%
HIV
31%
Human Immunodeficiency Virus 1 Infection
5%
Human Immunodeficiency Virus Infection
10%
Hyperimmune Globulin
5%
Immunoglobulin
5%
Inflammation
5%
Kidney Disease
9%
Liver Disease
11%
microRNA
5%
Monoclonal Antibody
15%
Morbidity
6%
Mortality
11%
Normal Human
5%
Placebo
9%
Remdesivir
5%
SARS Coronavirus
8%
Vaccine
13%